ClinicalTrials.gg

Graves Ophthalmopathy clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 200 studies for Graves Ophthalmopathy across more than 10 countries. 59 are recruiting or about to start. 192 of them are mainly about Graves Ophthalmopathy (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

Status

Completed
80
Recruiting
38
Status unknown
25
Not yet recruiting
18
Terminated
15
Active, not recruiting
13

Phase

Phase 3
52
Phase 2
40
Phase 4
25
Phase 1
21
Early Phase 1
2

Where

China
55
United States
53
Italy
24
Spain
23
Germany
20
United Kingdom
19

Who develops what

Add Graves Ophthalmopathy to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 14 programs from 10 companies, 14 with this as their studies’ main aim; 7 with a live phase 3 study; 9 primary completions in the next 12 months. Compare Innovent Biologics, Amgen and Minghui Pharmaceutical here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
MethylprednisoloneRecent, limited
Evidence
  • NCT07265258 · Innovent Biologics, Inc. · Phase 4 · live · comparator · “Methylprednisolone” · registered Nov 2025
  • NCT01114503 · GlaxoSmithKline · Phase 2 · comparator · “Methylprednisolone” · registered Apr 2010
Pfizer17% of its industry studiesUS: off-patent, 3 generics marketed11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
MHB018A☆ Track6 live phase-3 studies: NCT07622108, NCT07622121, NCT06989918Minghui Pharmaceutical
IBI311☆ Track1 live phase-3 study: NCT07113262Innovent Biologics, Inc.
elegrobart☆ Track1 live phase-3 study: NCT07211776Zai Lab Limited
KHN939☆ Track2 live phase-3 studies: NCT07720648, NCT07720635Beijing Kanghong Biological Medicine Co., Ltd.
linsitinib☆ Track2 live phase-3 studies: NCT07753603, NCT06112340Sling Therapeutics, Inc.

The 5 in phase 3 with the nearest primary completion, of 14 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (9)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.MHB018A · Minghui Pharmaceutical · Phase 3 main aimNCT06989918 MHB018A Treatment in Patients With Active Thyroid Eye Disease — primary endpoint: Proptosis Responder Rate at Week 24 · 108 enrolled
  • 31 Dec 2026 est.IBI311 · Innovent Biologics, Inc. · Phase 3 main aimNCT07113262 A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease — primary endpoint: Proptosis response rate of the study eye · 111 enrolled
  • 6 Jan 2027 est.AMG 732 · Amgen · Phase 2 main aimNCT06401044 A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease — primary endpoint: Part A: Number of Participants With Treatment-emergent Adverse Events · 94 enrolled

6 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Graves Ophthalmopathy studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Corticosteroids 6 open · Statins 5 open · Tyrosine kinase inhibitors (TKIs) 3 open · Antithyroid drugs 1 open

Coming up

21studies finish main data collection within a year7 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger. 1 (3%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 9 (24%) take healthy volunteers.

Recruiting studies that take each age, of 38
AgeWomenMen
101 (3%)1 (3%)
1837 (97%)37 (97%)
3038 (100%)38 (100%)
4038 (100%)38 (100%)
5038 (100%)38 (100%)
6538 (100%)38 (100%)
7533 (87%)33 (87%)
8510 (26%)10 (26%)

Across all 200 studies, recruiting or not: 39% stop at 75 or younger and 8% at 65; 3% take children; 1% are for women only and 0% for men only; 14% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Graves Ophthalmopathy studies take

Of 29 phase 3 interventional studies under Graves Ophthalmopathy, half reached primary completion within 18 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 318 mo14–25 · 29 studies——
Observational47 mo43–59 · 21 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 200. Browse all 200 → or search them.